1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC).

Autor:	Wakelee, H.1 (AUTHOR), Reck, M.2 (AUTHOR), Felip, E.3 (AUTHOR), Altorki, N.K.4 (AUTHOR), Vallieres, E.5 (AUTHOR), Liersch, R.6 (AUTHOR), Oizumi, S.7 (AUTHOR), Tanaka, H.8 (AUTHOR), Hamm, J.T.9 (AUTHOR), McCune, S.10 (AUTHOR), Bennett, E.11 (AUTHOR), Gitlitz, B.J.12 (AUTHOR), McNally, V.A.13 (AUTHOR), Novello, S.14 (AUTHOR), Ballinger, M.15 (AUTHOR), Zou, W.16 (AUTHOR), Nabet, B.17 (AUTHOR), Srivastava, M.15 (AUTHOR), Zhou, C.18 (AUTHOR)
Zdroj:	Annals of Oncology. 2024 Supplement 2, Vol. 35, pS779-S780. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu